Le Lézard
Classified in: Health
Subject: MRR

Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio


North America will account for 35% of the global interstitial cystitis (IC) drugs market

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report

Company Profiles

The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including:

Market Dynamics

The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample

Market Segmentation

Related Reports:

Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth.

Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this interstitial cystitis (IC) drugs market report?

Interstitial Cystitis Drugs Market Scope

Report Coverage

Details

Page number

160

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.9%

Market growth 2023-2027

USD 369.58 million

Market structure

Fragmented

YoY growth 2022-2023(%)

5.26

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 35%

Key countries

US, UK, Germany, Japan, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Allergan, Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Eli Lilly and Co., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd., Mission Pharmacal Co., Perrigo Co. Plc, Pfizer Inc., Purdue Pharma LP, Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and slow-growing segment analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio "Health Care" Research Reports

Table of Content

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio


These press releases may also interest you

at 15:17
Schools and colleges across the country rely on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) evaluations to assess and manage student-athlete concussions on the sidelines. However, this FDA-cleared tool is not recommended for...

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:05
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Martine Rothblatt PhD, JD, MBA, Chairperson and CEO of United Therapeutics, and inventor of SiriusXM Satellite Radio, will deliver the keynote address...

at 15:00
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...

at 15:00
Urban Wellness Group, a pioneering wellness provider, is proud to announce its official launch of new anti-aging and sleep enhancement treatments to southeast Portland. Dr. Jason Zabell and Dr. Andy Swanson set themselves apart by pairing over 30...

at 14:55
Peninsula Canada, a global leading HR and health & safety firm, committed to making a positive impact in the community, is proud to announce a partnership with SickKids Foundation, a leading charity dedicated to supporting The Hospital for Sick...



News published on and distributed by: